liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Nordic inflammatory bowel disease treatment strategy trial: protocol for the NORDTREAT randomised controlled biomarker-strategy trial
Orebro Univ, Sweden; Futurum Acad Hlth & Care, Sweden; Jonkoping Univ, Sweden.
Odense Univ Hosp, Denmark; Univ Southern Denmark, Denmark; Odense Univ Hosp, Denmark.
Landspitali Natl Univ Hosp Iceland, Iceland.
Odense Univ Hosp, Denmark; Univ Hosp Southern Denmark, Denmark; Bispebjerg & Frederiksberg Hosp, Denmark.
Show others and affiliations
2024 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 14, no 7, article id e083163Article in journal (Refereed) Published
Abstract [en]

Introduction The absence of reliable prognostic markers poses a challenge to the management of inflammatory bowel disease (IBD). Patients with aggressive disease may not receive sufficient treatment with conventional 'step-up' therapy, whereas a top-down approach may expose patients with indolent disease to unnecessary treatment-related toxicity. The objective of the Nordic IBD treatment strategy trial (NORDTREAT) is to assess the feasibility of personalised therapy by stratifying patients according to a prognostic serum protein signature at diagnosis.Methods and analysis NORDTREAT is a multicentre, biomarker-strategy design, open-label controlled trial. After screening consent, eligible patients are randomised (1:1) into one of two groups: a group with access to the protein signature and a group without access. In the access to protein signature group, patients displaying a protein signature suggestive of an increased risk of an aggressive disease course will be treated in line with a top-down treatment algorithm (anti-tumour necrosis factor agent with/without an immunomodulator). In contrast, those with a protein signature indicative of indolent disease will be excluded from the trial. Patients not in the access group receive treatment based on clinical management. This traditional management involves a stepwise escalation of treatment as determined by the investigator after failure of first-line treatment. After 52 weeks, outcomes are assessed in the subgroup of patients with a protein profile indicating a potentially severe disease trajectory. The primary endpoint is a composite of the proportion of patients with corticosteroid-free clinical and endoscopic remission at week 52. Surgical intervention due to IBD during follow-up will be defined as treatment failure.Ethics and dissemination Ethical approval has been obtained, and recruitment is underway at sites in four participating Nordic countries (Denmark, Iceland, Norway and Sweden). Following trial completion and data analysis, the trial results will be submitted for publication in peer-reviewed journals and presented at international conferences.Trial registration number NCT05180175; Pre-results. EudraCT number: 2019-002942-19.

Place, publisher, year, edition, pages
BMJ PUBLISHING GROUP , 2024. Vol. 14, no 7, article id e083163
Keywords [en]
inflammatory bowel disease; randomised controlled trial; prognosis
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-208009DOI: 10.1136/bmjopen-2023-083163ISI: 001311641300001PubMedID: 39089718OAI: oai:DiVA.org:liu-208009DiVA, id: diva2:1903463
Note

Funding Agencies|Nordforsk [90569]; Vinnova [2019-01185]; Innovation Fund Denmark [8114-00026B]; Rannis [90569, 199782-0611]; Research Council of Norway [2988039]; Oak Foundation [OCAY-18-774-OFIL]

Available from: 2024-10-04 Created: 2024-10-04 Last updated: 2025-04-23

Open Access in DiVA

fulltext(1480 kB)111 downloads
File information
File name FULLTEXT01.pdfFile size 1480 kBChecksum SHA-512
56db26b7f49b03ce0d24bdc29cf768983989bfea555b5799675fc1666d1b954e1ec76a22f06d525c1cd519218e184c04a2ec3330a5eef3700a9865a2c2756973
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Söderholm, Johan D
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesDepartment of Surgery in Linköping
In the same journal
BMJ Open
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 111 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 89 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf